搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
3 天
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop ...
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
Dunya News
15 小时
Study links air pollution to head, neck cancer risk
(Web Desk) - The harmful effects of air pollution on health, including an increased risk of cancer, have been well-documented ...
10 天
There's a Best Option for Patients With Head-and-Neck Cancer Who Can't Take Cisplatin
TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...
BlackDoctor
3 天
A Clinical Trial Found a Cisplatin Alternative for Head-and-Neck Cancers
A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.
16 小时
on MSN
Opioids interfere with cancer immunotherapy, but another type of drug could help
Opioids are often first-line treatments for cancer-related pain, but they can suppress the immune system and reduce the ...
Taiwan News
4 天
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at ...
Application error: a client-side exception has occurred (see the browser console for more information).
13 天
Srinagar, Anantnag Lead In Rising Head & Neck Cancer Cases In Kashmir
Srinagar- Head and neck cancers are on the rise in Kashmir, with Srinagar and Anantnag districts showing the highest number ...
1 天
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American ...
Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing ...
TMCnet
2 天
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of ...
BofA Securities, TD Cowen, Stifel, Cantor and William Blair are acting as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital, BTIG and Jones are acting as co-managers for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈